Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Fast track designation is big news....where are the pumpers?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(169)
•••
Comment by Kswdeluxon Dec 01, 2022 11:05am
237 Views
Post# 35143030

RE:Fast track designation is big news....where are the pumpers?

RE:Fast track designation is big news....where are the pumpers?
Aprilstocksgoup wrote: Canada?  West? kws? fox


Very exciting !

ONC has FAST TRACK designation in both mBC and now Panc.

FAST TRACK for mBC was designated in around 2016. Then AWARE-1 and BRACELET-1 were added to de-risk the mBC. Which is where the bio-markers were discovered and used in GOBLET.

Biomarkers were used in Panc and thus every paitient responded. Huge!

Lets see what comes out of Dec 7th with AN and the last of AWARE-1.

Next steps... not sure which will come first... Phase II/III Gastro registration by accelerated approval or Roche stepping up to the plate... but in any case... IMHO Panc is now offically ahead of mBC as mBC is hung up by Pfizer's 90 day exclusivity.

The market is taking notice !!!! How can they not now......

Cheers everyone, this has been a long haul, and even closer now....










<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities